This first approved pharmacologic treatment for IRDs caused by RPE65 mutations constituted a breakthrough therapy, and other therapies for a range of rare IRDs are now under clinical assessment (Prado et al., 2020). This evidence concerns the gene RPE65 and respiratory distress syndrome in premature infants.